HK1129394A1 - Hepatocyte growth factor (hgf) binding proteins - Google Patents

Hepatocyte growth factor (hgf) binding proteins

Info

Publication number
HK1129394A1
HK1129394A1 HK09107469.8A HK09107469A HK1129394A1 HK 1129394 A1 HK1129394 A1 HK 1129394A1 HK 09107469 A HK09107469 A HK 09107469A HK 1129394 A1 HK1129394 A1 HK 1129394A1
Authority
HK
Hong Kong
Prior art keywords
hgf
growth factor
binding proteins
hepatocyte growth
hepatocyte
Prior art date
Application number
HK09107469.8A
Other languages
English (en)
Inventor
May Han
S Kirk Wright
William M Winston Jr
Lyne Breault
Jie Lin
Bijan Etemad-Gilbertson
Christine Knuehl
Jeno Gyuris
Original Assignee
Aveo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aveo Pharmaceuticals Inc filed Critical Aveo Pharmaceuticals Inc
Publication of HK1129394A1 publication Critical patent/HK1129394A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK09107469.8A 2006-06-02 2009-08-13 Hepatocyte growth factor (hgf) binding proteins HK1129394A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81071406P 2006-06-02 2006-06-02
US86046106P 2006-11-21 2006-11-21
PCT/US2007/012950 WO2007143098A2 (en) 2006-06-02 2007-06-01 Hepatocyte growth factor (hgf) binding proteins

Publications (1)

Publication Number Publication Date
HK1129394A1 true HK1129394A1 (en) 2009-11-27

Family

ID=38802082

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09107469.8A HK1129394A1 (en) 2006-06-02 2009-08-13 Hepatocyte growth factor (hgf) binding proteins

Country Status (16)

Country Link
US (5) US7659378B2 (xx)
EP (2) EP2029627B1 (xx)
JP (2) JP4560582B2 (xx)
KR (1) KR101196184B1 (xx)
AR (1) AR061170A1 (xx)
AT (1) ATE533787T1 (xx)
AU (1) AU2007254853B2 (xx)
BR (1) BRPI0712223A2 (xx)
CA (1) CA2654019A1 (xx)
ES (1) ES2378097T3 (xx)
HK (1) HK1129394A1 (xx)
IL (2) IL195038A0 (xx)
MX (1) MX2008015138A (xx)
NO (1) NO20085422L (xx)
NZ (1) NZ573819A (xx)
WO (1) WO2007143098A2 (xx)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2029627B1 (en) * 2006-06-02 2011-11-16 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
SG158112A1 (en) * 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
DK2173379T3 (en) 2007-07-02 2015-12-07 Oncomed Pharm Inc Compositions and methods for treatment and diagnosis of cancer
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009148928A1 (en) 2008-05-29 2009-12-10 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
RU2010153578A (ru) * 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойными вариабельными доменами и их применение
KR20110016958A (ko) * 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2010005068A1 (ja) * 2008-07-10 2010-01-14 東レ株式会社 癌の治療及び予防用医薬組成物
DK2365828T3 (en) 2008-11-07 2014-12-08 Galaxy Biotech Llc Monoclonal antibodies against fibroblast second
SG2014010573A (en) * 2008-11-12 2014-04-28 Merck Sharp & Dohme ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
RU2012112550A (ru) 2009-09-01 2013-10-10 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
AR078651A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EA201390611A1 (ru) * 2010-11-24 2014-01-30 Глаксо Груп Лимитед Мультиспецифические антигенсвязывающие белки, направленные на hgf
CN104023746B (zh) 2011-07-15 2016-08-17 昂考梅德药品有限公司 Rspo结合剂和其应用
WO2013078223A1 (en) * 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
SG11201500233PA (en) 2012-07-13 2015-04-29 Oncomed Pharm Inc Rspo3 binding agents and uses thereof
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
CA2904743A1 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
EP3180027A4 (en) * 2014-08-15 2018-01-10 Oncomed Pharmaceuticals, Inc. Rspo1 binding agents and uses thereof
MA40574A (fr) 2014-09-16 2016-03-24 Oncomed Pharm Inc Traitement de maladies fibrotiques
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2016205566A1 (en) * 2015-06-16 2016-12-22 The Regents Of The University Of California Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
CA3039910A1 (en) 2016-03-28 2017-10-05 The Regents Of The University Of California Anti-ryk antibodies and methods of using the same
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
CN110785185B (zh) 2017-06-05 2024-05-24 詹森生物科技公司 具有非对称ch2-ch3区突变的工程化多特异性抗体和其他多聚体蛋白
US11597764B2 (en) 2017-06-15 2023-03-07 Memorial Sloan Kettering Cancer Center Anti-L1-CAM antibodies and uses thereof
KR102443358B1 (ko) 2017-12-06 2022-09-14 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
WO2019217450A1 (en) * 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020191293A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
EP4013869A1 (en) 2019-08-12 2022-06-22 InteRNA Technologies B.V. New treatments involving mirna-193a
US20230136088A1 (en) 2020-02-28 2023-05-04 Interna Technologies B.V. miRNA-193a for Promoting Immunogenic Cell Death
JP2023527638A (ja) 2020-03-27 2023-06-30 アビディティー バイオサイエンシーズ，インク． 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ATE503496T1 (de) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic Biosynthetisches bindeprotein für tumormarker
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
US6881557B2 (en) 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
KR101254371B1 (ko) * 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
RU2007146986A (ru) 2005-06-02 2009-06-27 ГЭЛЭКСИ БАЙОТЕК, ЭлЭлСи (US) Способы лечения опухолей головного мозга с использованием антител
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
SG158112A1 (en) 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
EP2029627B1 (en) 2006-06-02 2011-11-16 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
KR100829972B1 (ko) * 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법

Also Published As

Publication number Publication date
US20100173361A1 (en) 2010-07-08
US8575318B2 (en) 2013-11-05
US7659378B2 (en) 2010-02-09
US7935502B2 (en) 2011-05-03
NO20085422L (no) 2009-02-27
WO2007143098A8 (en) 2009-01-08
US20080038257A1 (en) 2008-02-14
IL219655A0 (en) 2012-06-28
AR061170A1 (es) 2008-08-06
US20140178934A1 (en) 2014-06-26
EP2380908A1 (en) 2011-10-26
ES2378097T3 (es) 2012-04-04
CA2654019A1 (en) 2007-12-13
AU2007254853A1 (en) 2007-12-13
EP2029627B1 (en) 2011-11-16
AU2007254853B2 (en) 2011-11-17
AU2007254853A2 (en) 2009-02-12
KR101196184B1 (ko) 2012-11-01
MX2008015138A (es) 2009-01-28
KR20090026315A (ko) 2009-03-12
US20130203970A1 (en) 2013-08-08
EP2029627A2 (en) 2009-03-04
ATE533787T1 (de) 2011-12-15
JP2010246565A (ja) 2010-11-04
IL195038A0 (en) 2011-08-01
JP2009539348A (ja) 2009-11-19
NZ573819A (en) 2011-09-30
BRPI0712223A2 (pt) 2012-07-10
US8268315B2 (en) 2012-09-18
JP5528246B2 (ja) 2014-06-25
JP4560582B2 (ja) 2010-10-13
WO2007143098A3 (en) 2008-06-12
WO2007143098A2 (en) 2007-12-13
US20110236377A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
HK1129394A1 (en) Hepatocyte growth factor (hgf) binding proteins
HK1129395A1 (en) Hepatocyte growth factor (hgf) binding proteins
HK1256740A1 (zh) 白介素-13結合蛋白
HK1217203A1 (zh) 白介素- 的結合成員
GB2449354B (en) Binding protein
NO20082564L (no) Hepatosyttvekstfaktorintronfusjonsproteiner
EP1776134A4 (en) C-MET KINASE BINDING PROTEINS
EP1789451A4 (en) TIE COMPLEX BINDING PROTEINS
GB0611116D0 (en) Proteins
IL188671A0 (en) Il-6 binding proteins
GB0601976D0 (en) Proteins
GB0610140D0 (en) Protein stability
GB0620735D0 (en) Proteins
GB0420963D0 (en) Hepatocyte
ZA200809483B (en) Hepatocyte growth factor (HGF) binding proteins
EP2024516A4 (en) Perforin-2 PROTEINS
GB0614682D0 (en) Proteins
GB0612623D0 (en) Proteins
GB0603878D0 (en) Hepatocyte culture

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160601